The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

Sarepta reported a quarter-on-quarter dip in sales for its Duchenne gene therapy. Elsewhere, Jazz won FDA approval of a brain cancer drug and Novo decided to advance a Prothena medicine into Phase 3.

The fundraise will help advance a cancer therapy that’s already shown early promise in people whose cancers haven’t responded ...

The initiative is a response to a Trump administration order to speed the construction of the type of new drug factories many ...

While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts ...

The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...

The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its ...

Pfizer's Albert Bourla told investors that major drugmakers are "ready to roll up their sleeves" and build out more direct-to ...

One vaccine expert called the move, which cancels some $500 million in messenger RNA research contracts, a “giant step ...

Since becoming Vertex's top scientist in 2015, Altshuler has shaped the company’s efforts to expand beyond cystic fibrosis.

The biotech industry needs to be supported by the government, by Congress,” Pfizer’s Albert Bourla told investors Tuesday in ...

The investment, which the foundation says is its largest in women’s health, will support research in maternal health, ...